Chongqing Lummy Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Chongqing Lummy Pharmaceutical has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 16.8% per year.
Key information
1.4%
Earnings growth rate
4.7%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -16.8% |
Return on equity | -0.1% |
Net Margin | -1.2% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Chongqing Lummy Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 850 | -10 | 560 | 94 |
31 Dec 23 | 896 | -9 | 595 | 100 |
30 Sep 23 | 858 | -86 | 575 | 80 |
30 Jun 23 | 932 | -74 | 670 | 75 |
31 Mar 23 | 913 | -46 | 657 | 72 |
01 Jan 23 | 885 | -69 | 654 | 81 |
30 Sep 22 | 1,004 | -158 | 769 | 103 |
30 Jun 22 | 1,020 | -182 | 742 | 113 |
31 Mar 22 | 1,064 | -176 | 773 | 116 |
31 Dec 21 | 1,225 | -101 | 853 | 100 |
30 Sep 21 | 1,404 | -307 | 970 | 135 |
30 Jun 21 | 1,597 | -286 | 1,058 | 118 |
31 Mar 21 | 1,695 | -270 | 1,099 | 109 |
31 Dec 20 | 1,584 | -327 | 1,039 | 107 |
30 Sep 20 | 1,632 | -231 | 1,035 | 166 |
30 Jun 20 | 1,662 | -217 | 1,059 | 165 |
31 Mar 20 | 1,795 | -184 | 1,135 | 165 |
31 Dec 19 | 1,859 | -155 | 1,113 | 164 |
30 Sep 19 | 1,801 | 74 | 1,008 | 42 |
30 Jun 19 | 1,669 | 71 | 891 | 44 |
31 Mar 19 | 1,548 | 73 | 759 | 43 |
31 Dec 18 | 1,562 | 98 | 754 | 43 |
30 Sep 18 | 1,477 | 95 | 730 | 31 |
30 Jun 18 | 1,440 | 93 | 642 | 45 |
31 Mar 18 | 1,363 | 79 | 571 | 36 |
31 Dec 17 | 1,282 | 56 | 492 | 31 |
30 Sep 17 | 1,169 | 21 | 377 | 23 |
30 Jun 17 | 1,074 | 18 | 342 | 0 |
31 Mar 17 | 990 | 10 | 311 | 0 |
31 Dec 16 | 990 | 7 | 309 | 0 |
30 Sep 16 | 966 | 53 | 285 | 0 |
30 Jun 16 | 970 | 42 | 271 | 0 |
31 Mar 16 | 974 | 34 | 267 | 0 |
31 Dec 15 | 964 | 21 | 261 | 0 |
30 Sep 15 | 999 | 40 | 230 | 0 |
30 Jun 15 | 999 | 45 | 228 | 0 |
31 Mar 15 | 992 | 36 | 230 | 0 |
31 Dec 14 | 912 | 9 | 228 | 0 |
30 Sep 14 | 820 | 1 | 223 | 0 |
30 Jun 14 | 756 | -1 | 209 | 0 |
31 Mar 14 | 743 | 19 | 205 | 0 |
31 Dec 13 | 759 | 61 | 195 | 0 |
30 Sep 13 | 698 | 51 | 190 | 0 |
30 Jun 13 | 662 | 57 | 183 | 0 |
Quality Earnings: 300006 is currently unprofitable.
Growing Profit Margin: 300006 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300006 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.
Accelerating Growth: Unable to compare 300006's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300006 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 300006 has a negative Return on Equity (-0.11%), as it is currently unprofitable.